HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 294/1/L131    most recent 00381.2007v2 00381.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kassel, K. M. Articles by Toews, M. L. Search for Related Content PubMed PubMed Citation Articles by Kassel, K. M. Articles by Toews, M. L.

Inhibition of human airway smooth muscle cell proliferation by β₂-adrenergic receptors and cAMP is PKA independent: evidence for EPAC involvement

¹Department of Pharmacology and Experimental Neuroscience and ²Pulmonary, Critical Care, Sleep, and Allergy Section, University of Nebraska Medical Center, Omaha, Nebraska; and ³Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Submitted 12 September 2007 ; accepted in final form 3 November 2007

Mechanisms by which β-adrenergic receptor (βAR) agonists inhibit proliferation of human airway smooth muscle (HASM) cells were investigated because of their potential relevance to smooth muscle hyperplasia in asthma. We hypothesized that βAR agonists would inhibit mitogenesis in HASM cells via the β₂AR, an increase in cAMP, and PKA activation. HASM cells were treated for 24 h with various agents and then analyzed for [³H]thymidine incorporation as a measure of cell proliferation. EGF stimulated proliferation by 10-fold. The nonselective βAR agonist isoproterenol and the β₂AR-selective agonists albuterol and salmeterol inhibited EGF-stimulated proliferation by more than 50%, with half-maximal effects at 4.8 nM, 110 nM, and 6.7 nM, respectively. A β₂AR-selective antagonist inhibited the isoproterenol effect with 100-fold greater potency than a β₁AR-selective antagonist, confirming β₂AR involvement in the inhibition of proliferation. The cAMP-elevating agents PGE₂ and forskolin decreased EGF-induced proliferation, suggesting cAMP as the mediator. β₂AR agonists and forskolin also inhibited proliferation stimulated by lysophosphatidic acid (LPA) as well as the synergistic proliferation stimulated by LPA+EGF. Importantly, PKA-selective cAMP analogs did not inhibit proliferation at concentrations that maximally activated PKA (10–100 µM), whereas a cAMP analog selective for the exchange protein directly activated by cAMP (EPAC), 8-(4-chlorophenylthio)-2'-O-methyl-cAMP, maximally inhibited proliferation at a concentration that did not activate PKA (10 µM). These data show that β₂AR agonists and other cAMP-elevating agents decrease proliferation in HASM cells via a PKA-independent mechanism, and they provide pharmacological evidence for involvement of EPAC or an EPAC-like cAMP effector protein instead.

exchange protein directly activated by cAMP; lysophosphatidic acid; epidermal growth factor; asthma

This article has been cited by other articles:

				K. M. Kassel, N. A. Schulte, and M. L. Toews Modulation of epidermal growth factor receptor binding to human airway smooth muscle cells by glucocorticoids and {beta}2-adrenergic receptor agonists Am J Physiol Lung Cell Mol Physiol, April 1, 2009; 296(4): L693 - L699. [Abstract] [Full Text] [PDF]

				S. K. Huang, S. H. Wettlaufer, J. Chung, and M. Peters-Golden Prostaglandin E2 Inhibits Specific Lung Fibroblast Functions via Selective Actions of PKA and Epac-1 Am. J. Respir. Cell Mol. Biol., October 1, 2008; 39(4): 482 - 489. [Abstract] [Full Text] [PDF]

				N. J. Fairbank, S. C. Connolly, J. D. MacKinnon, K. Wehry, L. Deng, and G. N. Maksym Airway smooth muscle cell tone amplifies contractile function in the presence of chronic cyclic strain Am J Physiol Lung Cell Mol Physiol, September 1, 2008; 295(3): L479 - L488. [Abstract] [Full Text] [PDF]